+

WO2006003526A3 - Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci - Google Patents

Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci Download PDF

Info

Publication number
WO2006003526A3
WO2006003526A3 PCT/IB2005/002630 IB2005002630W WO2006003526A3 WO 2006003526 A3 WO2006003526 A3 WO 2006003526A3 IB 2005002630 W IB2005002630 W IB 2005002630W WO 2006003526 A3 WO2006003526 A3 WO 2006003526A3
Authority
WO
WIPO (PCT)
Prior art keywords
otoa
gene
autism
diagnosis
prevention
Prior art date
Application number
PCT/IB2005/002630
Other languages
English (en)
Other versions
WO2006003526A2 (fr
WO2006003526A8 (fr
Inventor
Anne Philippi
Francis Rousseau
Peter Brooks
Joerg Hager
Original Assignee
Integragen Sa
Anne Philippi
Francis Rousseau
Peter Brooks
Joerg Hager
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa, Anne Philippi, Francis Rousseau, Peter Brooks, Joerg Hager filed Critical Integragen Sa
Publication of WO2006003526A2 publication Critical patent/WO2006003526A2/fr
Publication of WO2006003526A8 publication Critical patent/WO2006003526A8/fr
Publication of WO2006003526A3 publication Critical patent/WO2006003526A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'identification d'un gène humain de prédisposition à l'autisme pouvant être utilisé pour le diagnostic, la prévention et le traitement de l'autisme et de troubles associés, ainsi que pour le criblage de médicaments actifs sur le plan thérapeutique. Plus précisément, l'invention concerne le gène OTOA sur le chromosome 16 et certains allèles de celui-ci relatifs à la prédisposition à l'autisme et représentant de nouvelles cibles pour l'intervention thérapeutique. L'invention concerne des mutations spécifiques dans le gène OTOA et des produits d'expression, ainsi que des outils et des kits de diagnostic fondés sur ces mutations. Les produits de l'invention peuvent être utilisés dans le diagnostic de la prédisposition au syndrome d'Asperger, du trouble du développement profond, du retard mental, de l'anxiété, de la dépression, de troubles de l'hyperactivité avec déficit de l'attention, du retard de parole, de l'épilepsie, de trouble du métabolisme, de trouble immunitaire, de la maladie bipolaire et d'autres maladies psychiatriques et neurologiques et dans la détection, la prévention et/ou le traitement de ces maladies.
PCT/IB2005/002630 2004-07-01 2005-06-30 Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci WO2006003526A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58412704P 2004-07-01 2004-07-01
US60/584,127 2004-07-01

Publications (3)

Publication Number Publication Date
WO2006003526A2 WO2006003526A2 (fr) 2006-01-12
WO2006003526A8 WO2006003526A8 (fr) 2006-03-02
WO2006003526A3 true WO2006003526A3 (fr) 2006-06-15

Family

ID=35429403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002630 WO2006003526A2 (fr) 2004-07-01 2005-06-30 Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci

Country Status (1)

Country Link
WO (1) WO2006003526A2 (fr)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BARNBY GABRIELLE ET AL: "Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: Evidence of association at GRIN2A and ABAT", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 76, no. 6, June 2005 (2005-06-01), pages 950 - 966, XP002358259, ISSN: 0002-9297 *
CRAWFORD L ET AL: "Fine-scale SNP genotyping for Autism using Single Base Extension and tag arrays", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 4 Supplement, October 2001 (2001-10-01), & 51ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF HUMAN GENETICS; SAN DIEGO, CALIFORNIA, USA; OCTOBER 12-16, 2001, pages 508, XP002358258, ISSN: 0002-9297 *
CRAWFORD L R ET AL: "THE CHARACTERIZATION AND GENOTYPING OF SINGLE NUCLEOTIDE POLYMORPHISMS IN CODING REGIONS OF BRAIN-EXPRESSED AUTISM CANDIDATE GENES", AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, no. 4, SUPPL 2, October 2000 (2000-10-01), pages 351, XP001098557, ISSN: 0002-9297 *
DANIELS RACHAEL J ET AL: "Sequence, structure and pathology of the fully annotated terminal 2 Mb of the short arm of human chromosome 16", HUMAN MOLECULAR GENETICS, vol. 10, no. 4, 15 February 2001 (2001-02-15), pages 339 - 352, XP002358255, ISSN: 0964-6906 *
INTERNATIONAL MOLECULAR GENETIC STUDY OF AUTISM CONSORTIUM (IMGSAC): "A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 3, September 2001 (2001-09-01), pages 570 - 581, XP002358256, ISSN: 0002-9297 *
LAURITSEN M B ET AL: "The genetics of autism", ACTA PSYCHIATRICA SCANDINAVICA, vol. 103, no. 6, June 2001 (2001-06-01), pages 411 - 427, XP002358261, ISSN: 0001-690X *
SMALLEY SUSAN L ET AL: "Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 71, no. 4, October 2002 (2002-10-01), pages 959 - 963, XP002358257, ISSN: 0002-9297 *
ZWAENEPOEL INGRID ET AL: "Otoancorin, an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 9, 30 April 2002 (2002-04-30), pages 6240 - 6245, XP002358260, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2006003526A2 (fr) 2006-01-12
WO2006003526A8 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
IL179751A0 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
WO2008151803A3 (fr) Nouveaux polymorphismes du gène abcb1 associés à une absence de réaction clinique à des médicaments
WO2006087634A3 (fr) Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
IL179831A0 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
IL191311A (en) Transdermal therapeutic system and its use in the preparation of drugs for the prevention, treatment or delay of the progression of Alzheimer's disease, Parkinson's disease-related dementia and symptoms of traumatic brain injury
WO2006023719A3 (fr) Mutation genetique indiquant un risque accru de schizophrenie, de trouble schizo-affectif et de trouble bipolaire et applications pour le diagnostic et le traitement de ces maladies
WO2006096737A3 (fr) Cible diagnostique et therapeutique pour degenerescence maculaire
WO2005019474A3 (fr) Gene humain de susceptibilite a l'autisme et ses utilisations
WO2007132292A3 (fr) Thérapie pour la maladie d'alzheimer
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
WO2006090288A3 (fr) Genes humains de predisposition a l'autisme codant pour un transporteur de neurotransmetteur et utilisations associees
IL185868A0 (en) Human autism susceptibility gene encoding a transmembrane protein and uses thereof
Rikos et al. TREM2 R47H (rs75932628) variant is unlikely to contribute to Multiple Sclerosis susceptibility and severity in a large Greek MS cohort
WO2007017146A3 (fr) Utilisation de la collismycine et de derives de celle-ci comme inhibiteurs du stress oxydatif
WO2001020026A3 (fr) Polymorphismes du gene humain hpxr et leur utilisation dans des applications diagnostiques et therapeutiques
WO2006003526A8 (fr) Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci
WO2008070311A3 (fr) Examen de profil de l'expression génique de la maladie de parkinson
WO2007071437A3 (fr) Compositions et méthodes pour traiter des troubles inflammatoires
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
IL172229A (en) Use of pyrzolopyridines for the preparation of medicinal products to improve cognitive perception
WO2003097683A3 (fr) Gene humain de predisposition a l'obesite et utilisations dudit gene
WO2007044932A3 (fr) Techniques d'identification d'inhibiteurs de l'activite enzymatique
WO2005108605A3 (fr) Polymorphismes dans le gene abcb1 lies a un manque de reponse clinique a des medicaments
WO2001059152A3 (fr) Polymorphismes dans le gene humain cyp2b6 et leur utilisation dans des applications diagnostiques et therapeutiques
Youssof et al. Potential role of serotonin transporter gene (5-Htt) polymorphism in temporal lobe epilepsy susceptibility in egyptian patients.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 02/2006 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY."

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A) DATED 05-04-2007

122 Ep: pct application non-entry in european phase

Ref document number: 05774233

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载